Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00420615 | Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies | PHASE1 | COMPLETED | 34 | — | — | Dec 1, 2006 | - | Dec 8, 2020 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Patupilone and Omeprazole | EXPERIMENTAL | patupiloe + omeprazole |
| patupilone + midalzolam | EXPERIMENTAL | patupilone + midalzolam |
| Name | Type | Description |
|---|---|---|
| Patupilone and Omeprazole | DRUG | - |
| Patupilone + Midalzolam | DRUG | - |
Inclusion criteria: * Male or female patients 18 years or older * Histologically documented advanced solid tumor, who have failed standard systemic therapy, or for whom standard systemic therapy does not exist * Life expectancy of 3 months or more * Patients with adequate hematologic parameters Ex...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |